Jitka Bolchová, Despoina Gkentzi, Roberto Pedrero Tomé, Garyfallia Syridou, Antoni Noguera-Julián, María Ríos-Barnés, Serena Salomé, Francesco Raimondi, Serena Villaverde, Fernando Baquero-Artigao, Paula Rodriguez-Molino, Danilo Buonsenso, Laura Martino, Beatriz Álvarez-Vallejo, Jesús Saavedra, Yves Fougere, Hermione Lyall, Ina Foulon, Horst Buxmann, Simona Zanette, Olga Tsiatsiou, Jessica Wan, Daniel Blázquez-Gamero, Vana Papaevangelou
{"title":"Temporal trends in the clinical presentation, management, and outcomes of children with congenital cytomegalovirus infection.","authors":"Jitka Bolchová, Despoina Gkentzi, Roberto Pedrero Tomé, Garyfallia Syridou, Antoni Noguera-Julián, María Ríos-Barnés, Serena Salomé, Francesco Raimondi, Serena Villaverde, Fernando Baquero-Artigao, Paula Rodriguez-Molino, Danilo Buonsenso, Laura Martino, Beatriz Álvarez-Vallejo, Jesús Saavedra, Yves Fougere, Hermione Lyall, Ina Foulon, Horst Buxmann, Simona Zanette, Olga Tsiatsiou, Jessica Wan, Daniel Blázquez-Gamero, Vana Papaevangelou","doi":"10.1007/s00431-026-07485-2","DOIUrl":null,"url":null,"abstract":"<p><p>Congenital cytomegalovirus (cCMV) is the most common congenital infection and a leading cause of sensorineural hearing loss as well as neurodevelopmental impairment. In recent years, awareness, screening, and management strategies for cCMV have evolved. This study aimed to assess temporal changes in the clinical presentation, treatment, and outcomes of children diagnosed with cCMV infection. We conducted a retrospective cohort analysis using data from the CCMVnet registry ( www.ccmvnet.org ), an international multicenter database collecting anonymized data on children with confirmed cCMV infection. A total of 1653 patients diagnosed between 2011 and 2024 were included and divided into two cohorts: 2011-2016 (n = 566) and 2017-2024 (n = 1087). The year 2017 was selected as a pragmatic cutoff, corresponding to the year of publication of the European expert consensus statement on congenital CMV. Children were identified through antenatal, clinical, hearing-related, and newborn screening pathways. Symptomatic cCMV at birth was defined by the presence of at least one predefined clinical, laboratory, hearing, or neuroimaging finding based on previously published criteria. A comparative analysis between two distinct time periods was conducted, encompassing neonatal clinical findings, neuroimaging results, treatment strategies, and long-term outcomes. Newborns classified as symptomatic at birth decreased in the more recent cohort, from 49.2% in P1 to 44.2% in P2 (p = 0.07). The use of intravenous ganciclovir decreased from 7.3% to 2.8% (p < 0.001), while the use of oral valganciclovir alone increased from 43.8% to 78.7% (p < 0.001). Differences in long-term outcomes were observed between the two periods, with motor impairment at 12 months decreasing from 16.5% to 6.2% (p < 0.001) and any long-term sequelae at 36 months decreasing from 40.0% to 31.0% (p = 0.05).</p><p><strong>Conclusion: </strong> This study highlights temporal differences in the clinical spectrum, management, and outcomes of children with congenital CMV infection in Europe. The higher proportion of asymptomatic and mildly symptomatic children in the latter period may reflect changes in maternal and neonatal screening practices. The observed temporal differences provide insight into the evolving clinical landscape of cCMV diagnosis and management, while their underlying causes cannot be determined from the present data.</p><p><strong>What is known: </strong>• Congenital cytomegalovirus (cCMV) infection is the leading infectious cause of sensorineural hearing loss and neurodevelopmental impairment in children. • Clinical management of cCMV has evolved substantially over the last decade, particularly following the publication of the European expert consensus statement in 2017 and alongside expanding screening strategies.</p><p><strong>What is new: </strong>• In our cohort, children diagnosed with cCMV after 2017 presented with milder clinical manifestations and experienced fewer long-term sequelae than those diagnosed before 2017. • Temporal changes in diagnostic pathways, treatment practices, and clinical outcomes were observed between the two study periods.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 11","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00431-026-07485-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Congenital cytomegalovirus (cCMV) is the most common congenital infection and a leading cause of sensorineural hearing loss as well as neurodevelopmental impairment. In recent years, awareness, screening, and management strategies for cCMV have evolved. This study aimed to assess temporal changes in the clinical presentation, treatment, and outcomes of children diagnosed with cCMV infection. We conducted a retrospective cohort analysis using data from the CCMVnet registry ( www.ccmvnet.org ), an international multicenter database collecting anonymized data on children with confirmed cCMV infection. A total of 1653 patients diagnosed between 2011 and 2024 were included and divided into two cohorts: 2011-2016 (n = 566) and 2017-2024 (n = 1087). The year 2017 was selected as a pragmatic cutoff, corresponding to the year of publication of the European expert consensus statement on congenital CMV. Children were identified through antenatal, clinical, hearing-related, and newborn screening pathways. Symptomatic cCMV at birth was defined by the presence of at least one predefined clinical, laboratory, hearing, or neuroimaging finding based on previously published criteria. A comparative analysis between two distinct time periods was conducted, encompassing neonatal clinical findings, neuroimaging results, treatment strategies, and long-term outcomes. Newborns classified as symptomatic at birth decreased in the more recent cohort, from 49.2% in P1 to 44.2% in P2 (p = 0.07). The use of intravenous ganciclovir decreased from 7.3% to 2.8% (p < 0.001), while the use of oral valganciclovir alone increased from 43.8% to 78.7% (p < 0.001). Differences in long-term outcomes were observed between the two periods, with motor impairment at 12 months decreasing from 16.5% to 6.2% (p < 0.001) and any long-term sequelae at 36 months decreasing from 40.0% to 31.0% (p = 0.05).
Conclusion: This study highlights temporal differences in the clinical spectrum, management, and outcomes of children with congenital CMV infection in Europe. The higher proportion of asymptomatic and mildly symptomatic children in the latter period may reflect changes in maternal and neonatal screening practices. The observed temporal differences provide insight into the evolving clinical landscape of cCMV diagnosis and management, while their underlying causes cannot be determined from the present data.
What is known: • Congenital cytomegalovirus (cCMV) infection is the leading infectious cause of sensorineural hearing loss and neurodevelopmental impairment in children. • Clinical management of cCMV has evolved substantially over the last decade, particularly following the publication of the European expert consensus statement in 2017 and alongside expanding screening strategies.
What is new: • In our cohort, children diagnosed with cCMV after 2017 presented with milder clinical manifestations and experienced fewer long-term sequelae than those diagnosed before 2017. • Temporal changes in diagnostic pathways, treatment practices, and clinical outcomes were observed between the two study periods.
期刊介绍:
The European Journal of Pediatrics (EJPE) is a leading peer-reviewed medical journal which covers the entire field of pediatrics. The editors encourage authors to submit original articles, reviews, short communications, and correspondence on all relevant themes and topics.
EJPE is particularly committed to the publication of articles on important new clinical research that will have an immediate impact on clinical pediatric practice. The editorial office very much welcomes ideas for publications, whether individual articles or article series, that fit this goal and is always willing to address inquiries from authors regarding potential submissions. Invited review articles on clinical pediatrics that provide comprehensive coverage of a subject of importance are also regularly commissioned.
The short publication time reflects both the commitment of the editors and publishers and their passion for new developments in the field of pediatrics.
EJPE is active on social media (@EurJPediatrics) and we invite you to participate.
EJPE is the official journal of the European Academy of Paediatrics (EAP) and publishes guidelines and statements in cooperation with the EAP.